Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1953 2
1956 1
1957 1
1959 2
1960 1
1964 2
1965 1
1966 3
1967 3
1968 3
1969 2
1970 3
1971 3
1972 6
1973 4
1974 6
1975 11
1976 13
1977 14
1978 13
1979 20
1980 24
1981 32
1982 41
1983 42
1984 58
1985 69
1986 77
1987 50
1988 56
1989 72
1990 67
1991 69
1992 64
1993 95
1994 100
1995 132
1996 190
1997 240
1998 222
1999 275
2000 283
2001 324
2002 365
2003 353
2004 387
2005 485
2006 442
2007 474
2008 465
2009 485
2010 588
2011 677
2012 740
2013 775
2014 849
2015 960
2016 796
2017 819
2018 856
2019 935
2020 947
2021 941
2022 964
2023 916
2024 427

Text availability

Article attribute

Article type

Publication date

Search Results

15,966 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hematopoietic and lymphoid cell neoplasm"
Page 1
Emergencies in haematology: tumour lysis syndrome.
Durani U, Hogan WJ. Durani U, et al. Br J Haematol. 2020 Feb;188(4):494-500. doi: 10.1111/bjh.16278. Epub 2019 Nov 27. Br J Haematol. 2020. PMID: 31774551 Free article. Review.
COVID-19 in patients with hematologic malignancy.
Langerbeins P, Hallek M. Langerbeins P, et al. Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251. Blood. 2022. PMID: 35544585 Free PMC article.
Active immunization is an essential pillar to prevent SARS-CoV-2 infections in patients with hematologic malignancy. However, the immune response to SARS-CoV-2 vaccines may be significantly impaired, as only half of patients with hematologic malignancy develop a mea …
Active immunization is an essential pillar to prevent SARS-CoV-2 infections in patients with hematologic malignancy. However, the imm …
Recommendations on the use of azole antifungals in hematology-oncology patients.
Azanza JR, Mensa J, Barberán J, Vázquez L, Pérez de Oteyza J, Kwon M, Yáñez L, Aguado JM, Cubillo Gracian A, Solano C, Ruiz Camps I, Fortún J, Salavert Lletí M, Gudiol C, Olave Rubio T, Solano C, García-Vidal C, Rovira Tarrats M, Suárez-Lledó Grande M, González-Sierra P, Dueñas Gutiérrez C. Azanza JR, et al. Rev Esp Quimioter. 2023 Jun;36(3):236-258. doi: 10.37201/req/013.2023. Epub 2023 Apr 5. Rev Esp Quimioter. 2023. PMID: 37017117 Free PMC article. Review.
One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematologic tumors, with serious complications. In this regard, acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporin …
One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematolo …
Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.
Wudhikarn K, Perales MA. Wudhikarn K, et al. Bone Marrow Transplant. 2022 Oct;57(10):1477-1488. doi: 10.1038/s41409-022-01756-w. Epub 2022 Jul 15. Bone Marrow Transplant. 2022. PMID: 35840746 Free PMC article. Review.
CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy providing excellent remission rates and durable disease control for patients with relapsed/refractory (R/R) hematologic malignancies. ...Fortunately, although studies show a high inc …
CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy providing excellent remission rates and durable d …
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M. Cordeiro A, et al. Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13. Biol Blood Marrow Transplant. 2020. PMID: 31419568 Free PMC article. Clinical Trial.
CD19-targeted chimeric antigen receptor-modified T cell (CAR-T cell) therapy has shown excellent antitumor activity in patients with relapsed/refractory B cell malignancies, with very encouraging response rates and outcomes. ...Graft-versus-host disease occur …
CD19-targeted chimeric antigen receptor-modified T cell (CAR-T cell) therapy has shown excellent antitumor activity in patient …
T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies.
Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M. Vadillo E, et al. Blood Rev. 2018 Jan;32(1):36-51. doi: 10.1016/j.blre.2017.08.006. Epub 2017 Aug 15. Blood Rev. 2018. PMID: 28830639 Review.
T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% and 25% of total childhood and adult ALL cases, respectively. ...Here, we summarize current knowledge about molecular mechanisms of leukemic T-cell infiltration with special emphasis on the newly identifie …
T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% and 25% of total childhood and adult ALL cases, respectively. ...Here, w …
Hereditary myeloid malignancies.
Rafei H, DiNardo CD. Rafei H, et al. Best Pract Res Clin Haematol. 2019 Jun;32(2):163-176. doi: 10.1016/j.beha.2019.05.001. Epub 2019 May 3. Best Pract Res Clin Haematol. 2019. PMID: 31203998 Free PMC article. Review.
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.
Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, Arcila ME, Ladanyi M, Tallman MS, Levine RL, Berger MF. Coombs CC, et al. Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4. doi: 10.1016/j.stem.2017.07.010. Epub 2017 Aug 10. Cell Stem Cell. 2017. PMID: 28803919 Free PMC article.
Clonal hematopoiesis (CH), as evidenced by recurrent somatic mutations in leukemia-associated genes, commonly occurs among aging human hematopoietic stem cells. We analyzed deep-coverage, targeted, next-generation sequencing (NGS) data of paired tumor and blood samples fro …
Clonal hematopoiesis (CH), as evidenced by recurrent somatic mutations in leukemia-associated genes, commonly occurs among aging human he …
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin PJ, Przepiorka D, Pusic I, Dignan F, Mitchell SA, Lawitschka A, Jacobsohn D, Hall AM, Flowers ME, Schultz KR, Vogelsang G, Pavletic S. Lee SJ, et al. Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99. doi: 10.1016/j.bbmt.2015.02.025. Epub 2015 Mar 19. Biol Blood Marrow Transplant. 2015. PMID: 25796139 Free PMC article.
Maintenance Strategies After Hematopoietic Cell Transplantation.
Culos KA, Gatwood KS, Byrne M. Culos KA, et al. Pharmacotherapy. 2020 Aug;40(8):727-740. doi: 10.1002/phar.2407. Epub 2020 May 19. Pharmacotherapy. 2020. PMID: 32343426 Review.
Hematopoietic cell transplantation (HCT) is an essential component of potentially curative therapy for patients with hematologic malignancies. High-dose chemotherapy with autologous (auto) stem cell rescue is used to overcome chemoresistance in multipl …
Hematopoietic cell transplantation (HCT) is an essential component of potentially curative therapy for patients with hemato …
15,966 results
You have reached the last available page of results. Please see the User Guide for more information.